Research
Evidence reviews across peptides, GLP-1 medications, and longevity therapeutics. No secondary summaries — every claim traced to the trial, the label, or the paper of record.
Peptide evidence matrix
Every peptide graded by how strong the human evidence actually is — filter by tier, source on each grade.
GLP-1 weight-loss comparison
Every GLP-1 and incretin drug ranked by mean trial weight loss — filter, sort, tap through to the source.
Pentadeca Arginate (PDA): the evidence behind the BPC 157 successor
PDA is marketed as a more stable upgrade on BPC 157 — but it has almost no research of its own. A straight read of a borrowed evidence base.
6 min readLongevityFOXO4-DRI: an elegant senolytic peptide with zero human evidence
A rationally designed peptide that frees p53 to kill senescent cells and reversed features of aging in mice — but rests on essentially one landmark study, has no human trials, and is sold gray-market with no safety basis.
6 min readPeptidesGHRP-2: a real GH secretagogue, marketed for things it hasn't been shown to do
GHRP-2 (pralmorelin) genuinely raises growth hormone and is an approved diagnostic agent in Japan — but the same dose lifts cortisol, ACTH and prolactin, drives appetite, and desensitizes with daily use. A straight read of the human data behind the anti-aging marketing.
6 min readPeptidesGHRP-6: the 'hunger' growth-hormone secretagogue, and what the evidence shows
GHRP-6 is a first-generation ghrelin-receptor agonist that pulses growth hormone — but its most reliable real-world effect is a strong, dose-dependent surge in appetite. Real short-term GH pharmacology, preclinical cytoprotection, no long-term human outcomes, and not FDA-approved.
6 min readPeptidesP21 (P021): a neurogenic peptide with real animal data and no human evidence
Marketed as “P21,” the compound is really P021 — a CNTF-derived peptide that boosts neurogenesis in rodents. There are no human trials, no approval, and a genuinely muddled name. A straight read of where the science stands.
6 min readPeptidesOxytocin: real science, oversold claims
The 'bonding hormone' has a huge human literature — and its most famous findings largely failed to replicate. A straight read of where the evidence stands.
6 min readGLP-1The SELECT trial, explained: semaglutide and heart outcomes without diabetes
How a 17,604-person trial showed semaglutide 2.4 mg cut major cardiovascular events by about 20% — and what the modest absolute benefit really means.
6 min readGLP-1SURMOUNT-1 explained: the trial that made tirzepatide the benchmark
The landmark phase 3 trial of tirzepatide for obesity — the design, the up-to-20.9% weight loss, the safety profile, and the limits of what it proved.
6 min readGLP-1SUSTAIN-6 explained: the trial that first hinted at semaglutide's heart benefit
A safety study designed to rule out cardiovascular harm instead signaled benefit (MACE HR 0.74) — while flagging a real diabetic-retinopathy caveat. Read straight from the primary source.
6 min readGLP-1STEP-HFpEF, explained: can semaglutide treat obesity-related heart failure?
The trial that tested whether semaglutide improves symptoms and function — not just weight — in obesity-phenotype HFpEF, read straight from the primary source.
6 min readLongevityThe CALERIE trial explained: what a 2-year test of caloric restriction actually showed
The landmark randomized trial of sustained caloric restriction in healthy adults moved aging biology in the right direction — but participants hit only about 12% of a 25% target, and it measured biomarkers, not lifespan.
6 min readLongevityThe NIA Interventions Testing Program: the gold standard for longevity claims
How the ITP tests compounds for lifespan in genetically diverse mice across three blinded labs — what passed (rapamycin, acarbose, canagliflozin), what failed (resveratrol), and why it is the benchmark.
6 min readGLP-1Retatrutide side effects: what the Phase 2 trials actually reported
Dose-related gastrointestinal events dominate, with a transient glucagon-linked rise in heart rate — all from Phase 2. No long-term safety data, no approved product, and gray-market risk on top.
6 min readLongevityTUDCA side effects: generally well tolerated, with real limits
In the human trials that exist, TUDCA is well tolerated — the reported effects are mild and gastrointestinal — but its parent drug UDCA at high doses had a safety signal, absorption interactions matter, and long-term human safety data are limited.
6 min readPeptidesIpamorelin side effects: mild on paper, thin on data, and a gray-market catch
The peptide's own reported effects are mostly mild and transient — but the human safety record is thin, the GH-axis concerns are real, and the biggest risk is that it's unapproved and sold gray-market.
6 min readPeptidesCJC-1295 side effects: what's measured, what's inferred, and the DAC concern
Injection-site reactions and flushing are the commonly reported effects; fluid retention, carpal-tunnel-like tingling, and glucose changes are inferred from GH excess. The DAC's real signature is a raised, non-pulsatile GH trough.
6 min readLongevityRapamycin side effects: the approved-use profile and the longevity-dose nuance
Mouth ulcers, raised lipids and glucose, infection risk and impaired wound healing come straight from sirolimus's transplant label — but low intermittent longevity dosing looks better tolerated, if unproven long-term.
6 min readLongevityUrolithin A side effects: a clean record, but short trials
Urolithin A (Mitopure) was well tolerated across the human RCTs — adverse events comparable to placebo, no serious events, GRAS status. The honest catch is that those trials ran weeks to months, so long-term safety is unestablished.
6 min readLongevitySpermidine side effects: well tolerated, and one theoretical caveat
In the human trials spermidine's adverse events ran level with placebo — mild and mostly gastrointestinal. The polyamine/cancer concern is theoretical and unproven; the concrete flags are a wheat-germ allergen and the absence of long-term data.
6 min readLongevityFisetin side effects: well tolerated, with honest cautions
Fisetin is generally well tolerated — long dietary history, low animal toxicity, no adverse events in the one human study. The real caveats are mild GI upset at high doses, a theoretical CYP drug-interaction flag, and the unproven long-term safety of experimental senolytic doses.
6 min readLongevityCerebrolysin side effects: well tolerated, with one serious flag
The trials rated it reasonably tolerated and the common effects are mild and infusion-related — but Cochrane flagged a possible increase in non-fatal serious adverse events, and its porcine source carries a rare anaphylaxis risk.
6 min readLongevityGlutathione side effects: oral is benign, injectable skin-whitening is not
Oral glutathione is generally well tolerated. The honest safety issue is unregulated IV and injectable glutathione sold for skin-whitening — an unapproved use that regulators have warned about, tied to severe skin reactions, thyroid and kidney effects, and infection risk.
6 min readLongevityLithium orotate: an intriguing population signal, almost no direct evidence
Trace lithium in drinking water tracks with lower suicide and dementia rates — but that's an association, and lithium orotate itself has essentially no controlled human trials.
6 min readLongevityCoQ10: strong cardiac evidence, hype everywhere else
The Q-SYMBIO trial cut mortality in heart failure — but statin-muscle data are mixed, migraine support is moderate, and the anti-aging pitch rests on a decline, not an outcome.
6 min readLongevityPQQ evidence: a strong mitochondrial mechanism, thin human data
PQQ activates the PGC-1α biogenesis pathway in the lab — but the human case is a few small, short, partly industry-run trials with no healthspan outcomes.
6 min readLongevityApigenin: what the evidence says about sleep, anxiety, and the NAD+ longevity claim
A plausible GABA-A mechanism and a CD38/NAD+ longevity hypothesis — but the human data are mostly from chamomile and preclinical models, not isolated apigenin.
6 min readLongevityKlotho, the longevity protein: strong biology, no supplement you can buy
Klotho suppresses aging in mice, tracks with human longevity and cognition, and boosted cognition in aged monkeys in 2023 — but it's a large protein you can't take orally.
6 min readPeptidesLarazotide: the leaky-gut peptide that failed its Phase 3 trial
An 8-amino-acid tight-junction regulator with real celiac data and a failed pivotal trial — and why the supplement use runs far ahead of the evidence.
6 min readPeptidesThymalin: the honest evidence behind the thymus-peptide immunity and longevity claims
Marketed for immune restoration and longer life. The supporting science is old, small, and almost entirely from one Russian program — and unreplicated.
6 min readPeptidesLL-37: a real immune peptide, no human proof, and two edges
The human cathelicidin is genuine innate-immunity biology — but its therapeutic use is preclinical, and the same peptide is implicated in inflammatory disease.
6 min readGLP-1Ecnoglutide (XW003): the cAMP-biased GLP-1 agonist and its China phase 3 data
An investigational, once-weekly GLP-1 receptor agonist engineered to bias signalling toward cAMP — with about 13% weight loss and competitive diabetes results in Chinese phase 3 trials. A straight read of the evidence and its limits.
6 min readLongevityErgothioneine: the mushroom-derived “longevity vitamin,” assessed
A diet-derived antioxidant with its own transporter and encouraging epidemiology — but no outcome trials. A straight read of what the evidence supports and where it stops.
6 min readGLP-1Semaglutide vs liraglutide: what the head-to-head trials actually show
Two Novo GLP-1 drugs — daily liraglutide and weekly semaglutide. STEP 8 and SUSTAIN 10 compared them directly; here is the honest read on potency, dosing and where each still fits.
6 min readLongevityNMN vs NR: the two leading NAD⁺ precursors, head-to-head
Both reliably raise NAD⁺ markers in humans; neither has proven longevity outcomes. A straight comparison on pathway, absorption, the human trial record, and the FDA wrinkle that decides which you can buy.
6 min readPeptidesAre peptides safe? It depends on which peptide — and which vial
Approved peptide drugs have known, bounded safety profiles from human trials. Gray-market “research” peptides carry a different risk: unverified purity, contamination, non-sterile injection and no oversight. An honest split of the two questions.
7 min readLongevitySS-31 (elamipretide) dosage: what the trials actually used
The elamipretide trials converged on 40 mg once daily, injected subcutaneously — but that is a studied dose in serious disease, not an approved dose for anti-aging or general use. The honest numbers, and why the gray-market version is risky.
5 min readLongevityCerebrolysin dosage: the regimens trials actually used
In the largest stroke trials the dose was 30 mL/day by IV infusion, over 10-to-21-day courses. But there's no FDA-approved dose, the pooled evidence shows no benefit on death, and it's a clinician-administered drug — not a home protocol.
6 min readGLP-1Orforglipron dosage: the doses studied, and what the label actually covers
Orforglipron is a once-daily oral non-peptide GLP-1 — now FDA-approved for weight management. What can be described precisely is how it was dosed in the Phase 2/3 trials: once daily, no food or water rules, titrated up to 36 mg — and why.
5 min readLongevitySpermidine dosage: the trials used about 1 mg a day
Human cognition trials used a wheat-germ extract at 0.9–1.2 mg spermidine/day — and the most rigorous one was null. Sold products run higher (~1–6 mg/day) with no dedicated trials, and there's no established anti-aging dose.
6 min readLongevityUrolithin A dosage: the doses the trials actually used
The human RCTs used 500 mg or 1,000 mg once daily, oral — 1,000 mg ran through every muscle trial. You dose the finished metabolite (Mitopure) to bypass unreliable gut conversion. Well tolerated, but a supplement, not a proven strength drug.
6 min readLongevityFisetin dosage: the “hit-and-run” trial protocol vs the supplement bottle
The senolytic dose being tested in humans is a ~20 mg/kg burst for two days, repeated monthly — roughly 1400 mg on a trial day for a 70 kg adult, and nothing like the 100–500 mg/day sold OTC. It's also experimental, with no published human outcomes.
6 min readGLP-1Survodutide (BI 456906): the GLP-1 / glucagon dual agonist and its Phase 2 data
An investigational dual agonist that adds glucagon to GLP-1 — with about 15% weight loss and standout MASH results in Phase 2. A straight read of the evidence and its limits.
6 min readGLP-1Mazdutide: the GLP-1/glucagon dual agonist approved in China
A once-weekly GLP-1 and glucagon dual agonist from Innovent, licensed from Eli Lilly. What the GLORY-1 Phase 3 data show — and exactly where it is and isn't approved.
6 min readGLP-1Amycretin: what the early GLP-1 + amylin co-agonist data actually show
Novo Nordisk's unimolecular GLP-1 and amylin agonist posted large weight-loss numbers in Phase 1 — subcutaneous and oral. A straight read of the evidence, and how early it really is.
6 min readGLP-1Pemvidutide: the GLP-1/glucagon dual agonist betting on lean-mass preservation
Altimmune's investigational dual agonist isn't chasing the biggest weight-loss number — it's chasing better body composition and liver benefit. A straight read of the Phase 2 evidence.
6 min readGLP-1Retatrutide dosage: the doses studied, and why there is no approved one
Retatrutide is investigational and not approved anywhere, so there is no official dose. What can be described is how it was dosed in the Phase 2 trials — once weekly, escalated slowly up to 12 mg — and why.
6 min readLongevityCerebrolysin: what it is, and what the evidence actually shows
A porcine-brain-derived peptide mixture sold abroad for stroke and dementia — and pitched online as a nootropic. A straight read of the Cochrane reviews and the regulatory reality.
6 min readLongevitySS-31 (elamipretide): an elegant mitochondrial mechanism meets a hard clinical record
A cardiolipin-binding peptide with a beautiful mechanism and a mostly disappointing trial history — including a failed myopathy trial and a narrow, confirmation-pending Barth syndrome approval. A straight read.
6 min readLongevitySLU-PP-332: the “exercise mimetic” that lives entirely in mice
A synthetic pan-agonist of the ERRα/β/γ receptors switches on an endurance-training program — in rodents and cell culture. A straight read of the preclinical evidence, and why there is no human story yet.
6 min readGLP-1Zepbound (tirzepatide) side effects: the label-anchored rundown
Nausea leads the common reactions, but the label also carries a boxed thyroid-tumor warning and serious risks. What the FDA prescribing information and SURMOUNT-1 actually say.
7 min readGLP-1Where to buy retatrutide: the honest answer is you can’t
Retatrutide is investigational and not approved anywhere — so there is no legitimate place to buy it. The only lawful access is a clinical trial. Here is the sober reality of the gray market, and the approved alternatives available now.
6 min readGLP-1Zepbound for sleep apnea: the first drug approved for OSA, and what the trials show
In December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. A straight read of the SURMOUNT-OSA evidence and its limits.
6 min readGLP-1Ozempic and gallbladder problems: what the evidence really shows
GLP-1 drugs raise the risk of gallstones and gallbladder inflammation — a real, dose-related signal from randomized trials. The mechanisms, the modest absolute risk, and the symptoms that mean seek care now.
6 min readGLP-1The cheapest legitimate ways to get tirzepatide in 2026
LillyDirect self-pay vials run $299–$449 by dose; a covered plan plus the savings card can mean ~$25. Compounded tirzepatide is cheaper — and not FDA-approved. An honest map of the tradeoff.
6 min readGLP-1“Microdosing” GLP-1 drugs: a trend, not a protocol — what the dose-response evidence actually says
Sub-therapeutic semaglutide and tirzepatide is spreading fast. The pharmacology is clear, the honest part is clearer: efficacy is dose-related, and no trial has tested intentional microdosing.
6 min readGLP-1Oral tirzepatide: the honest status of a pill that does not exist yet
There is no FDA-approved oral tirzepatide. Here is why an oral peptide is hard, what the 'oral tirzepatide' sold online really is, and the oral incretins that actually exist.
6 min readLongevityNAD⁺ nasal spray: the delivery format with the least direct evidence
Intranasal NAD⁺ is convenient and heavily marketed — but no controlled human trial shows the spray raises systemic or brain NAD⁺. A straight comparison with the better-studied routes.
6 min readPeptidesPeptides for sleep: what actually has human evidence (and what doesn't)
DSIP, the GH-axis peptides and Selank all get marketed for sleep. Graded against controlled human data, none is an evidence-based sleep therapy — and the proven levers aren't injectable.
6 min readPeptidesPeptide injection sites: where subcutaneous shots go, and how to rotate them
Almost all research peptides and GLP-1s are injected subcutaneously — into the abdomen, outer thigh, back of the upper arm or upper buttock. A practical, harm-reduction guide to the sites, why you rotate them, and sterile-technique basics.
6 min readLongevityThe best berberine supplement: an evidence-first buyer’s guide
No fake lab rankings — just the verifiable criteria that actually separate a good berberine supplement from a bad one: form, dose, third-party testing, manufacturing and value.
6 min readLongevityThe best NAD⁺ supplement: an evidence-first buyer's guide
The honest answer is a precursor, not a “NAD⁺” pill. How to choose an NR or NMN supplement on verifiable criteria — proven ingredient, studied dose, third-party testing, price — and where the evidence stops.
6 min readGLP-1Semaglutide and GLP-1s for PCOS: what the evidence actually shows
PCOS runs on insulin resistance and weight — exactly what GLP-1s improve. A straight read of the RCTs and meta-analyses, the off-label reality, and the fertility caveat.
6 min readGLP-1Semaglutide for MASH: what the ESSENCE trial and the FDA approval actually say
Semaglutide 2.4 mg hit both liver endpoints in Phase 3 and won an FDA approval for MASH in 2025 — but for a specific F2–F3 population, under the accelerated pathway. A precise read of the evidence.
6 min readGLP-1Retatrutide vs tirzepatide vs semaglutide: the three-way, read honestly
One, two, three receptors — and roughly 15%, 21% and 24% weight loss. The mechanism ladder is real, but two drugs are approved and one is still investigational, and none were compared in the same trial.
6 min readPeptidesARA-290 (cibinetide): the EPO-derived repair peptide and what its trials actually show
An 11-amino-acid peptide engineered from erythropoietin to protect tissue without making red cells. A straight read of the small-fiber-neuropathy evidence — and its limits.
6 min readLongevityAcarbose and longevity: a carb-blocker with a real mouse-lifespan signal
An approved diabetes drug that repeatably extended lifespan in NIA mice — more in males. A straight read of the mouse data, the human gap, and the side-effect ceiling.
6 min readPeptidesPeptides for joint pain: what the human evidence actually shows
BPC-157, TB-500 and copper peptides are marketed for cartilage, tendon and ligament repair. Graded by real human evidence, the joint-pain ladder is nearly empty at the top.
6 min readPeptidesPeptides for anxiety: Selank, Semax and DSIP graded by real human evidence
Three peptides dominate the “peptides for anxiety” lists. Only one has meaningful human anxiety data — and none is approved or backed by large Western trials. A straight read.
6 min readPeptidesPeptides for hair growth: what the copper-peptide evidence actually shows
GHK-Cu has a plausible follicle mechanism and some lab data — but nothing rivaling minoxidil or finasteride. A straight read of the hair evidence, and the biotin and GLP-1 confusions around it.
6 min readPeptidesPeptides for skin: which cosmetic peptides actually have evidence
Topical skin peptides have the best consumer evidence of any peptide category. A graded, evidence-first read on GHK-Cu, Matrixyl and argireline — and realistic expectations.
6 min readLongevityGonadorelin vs hCG: Testosterone, Fertility, and Libido on TRT
Both keep the testicular axis on during TRT — but hCG mimics LH directly at the testis with real fertility data, while gonadorelin's once-daily bolus dosing fights the pulsatile pharmacology GnRH depends on.
7 min readPeptidesDo Growth Hormone Peptides Affect Libido? Sermorelin, Ipamorelin, MK-677 and the Evidence
The honest chain from a GH peptide to your sex drive runs through sleep, energy, and mood — an indirect effect at best, not a libido or erectile-dysfunction treatment.
6 min readLongevityEnclomiphene, Libido, and Erectile Function: What to Expect
Enclomiphene raises your own testosterone — so it can lift libido and erections, but only when low testosterone was the cause, not for normal-T men or vascular and psychogenic ED.
6 min readPeptidesBPC-157 and Erectile Dysfunction: Separating the Claims from the Evidence
BPC 157 is marketed for 'blood flow' and, by extension, erections — but the entire claim rests on animal mechanism with zero human sexual-function data.
6 min readGLP-1Ozempic, the Vulva and Vagina: What's Real and What's Hype
“Ozempic vagina” and “Ozempic vulva” are media terms, not drug effects — the real story is rapid-weight-loss volume loss and life stage, not an action on genital tissue.
7 min readGLP-1'Ozempic Babies': GLP-1s, Fertility, and Birth Control
Unexpected pregnancies on GLP-1 drugs come from two real mechanisms: weight loss restoring ovulation, and — for tirzepatide specifically — reduced absorption of oral contraceptives. Here's what the evidence and the labels actually say.
7 min readGLP-1Ozempic, Libido, and Erectile Dysfunction: What the Evidence Shows
GLP-1 drugs don't act on sex drive directly — they act on weight, and that cuts both ways: an evidenced upside for testosterone and erections, a real but under-studied libido downside, and why desire and erections are different problems.
7 min readPeptidesMelanotan II and Libido: The Erection Side Effect That Became a Drug
Melanotan II was built to tan skin — but its accidental effect on erections and desire, acting centrally via MC4R, is why the FDA-approved libido drug bremelanotide (PT-141) exists.
6 min readPeptidesKisspeptin and Libido: What the Brain-Imaging Trials Actually Found
Imperial College fMRI trials show kisspeptin enhances the brain's sexual-processing activity — a plausible, promising target, but early brain-imaging data, not a proven libido therapy.
6 min readLongevityApomorphine for ED: How It Works and What the Evidence Shows
A centrally-acting dopamine agonist that starts the erectile signal in the brain — its modest trial record, its withdrawn European approval, and why it still turns up in compounded telehealth combos.
6 min readLongevityIcariin and Horny Goat Weed: What the Evidence Actually Shows
A real PDE5 inhibitor in the test tube with coherent animal data — but weak potency, poor oral absorption, and essentially no rigorous human trials behind the “natural Viagra” label.
6 min readPeptidesBacteriostatic Water for Peptides: What It Is and How to Use It
Bacteriostatic water is sterile water plus ~0.9% benzyl alcohol — the preservative that lets a multi-dose vial be entered for about 28 days. Here is how it differs from sterile water and SWFI, why the preservative matters, and its real cautions.
6 min readPeptidesHow to Increase Deep Sleep: What the Evidence Actually Shows
Deep (slow-wave) sleep is front-loaded into the early night and drives your biggest growth-hormone pulse — here are the levers that actually raise it, and an honest look at where peptides fall short.
7 min readPeptidesWhat Are Peptides? A Plain-Language Guide to the Science
A short chain of amino acids — but where any given peptide falls between approved medicine and unproven research chemical is the whole story.
7 min readPeptidesAre Peptides Legal? US Status, the FDA, and 'Research-Only' Rules
Some peptides are FDA-approved prescription drugs; most popular research peptides are not — and 'research use only' is a legal framing, not a free pass. A careful, non-alarmist map of US status.
6 min readPeptidesHow to Heal Tendons Faster: What the Evidence Supports
Loading beats injections beats peptides: a straight, evidence-ranked guide to what actually helps a tendon recover — and what is just hype.
7 min readPeptidesBanned Peptides: The WADA Prohibited List, Explained
Why nearly every peptide is banned in sport — how WADA's S0 catch-all and S2 peptide-hormone category work, where BPC-157 stands, and how banned differs from illegal.
6 min readPeptidesHow to Read a Peptide Certificate of Analysis (COA)
HPLC purity, mass-spec identity, net peptide content, and the red flags — a buyer's guide to what a COA proves and what it can't.
6 min readPeptidesDo Peptides Show Up on a Drug Test?
Standard employment and clinical drug screens do not test for peptides — but elite-sport anti-doping labs specifically do. The honest answer depends on who is testing, and why.
5 min readPeptidesGrowth Hormone Secretagogues: GHRH Analogs vs GHRPs Explained
The umbrella category that makes your own pituitary release more GH — split into GHRH analogs and ghrelin-receptor GHRPs, why they're combined, and where the evidence stops.
7 min readPeptidesTB-500 dosage: why there isn't an approved one
There is no FDA-approved TB-500 and no official human dose. The real thymosin β4 trials used eye drops and wound gels, not recovery injections; the community protocol is anecdotal — and the peptide is banned in sport.
7 min readPeptidesGHK-Cu dosage: topical concentrations versus the unvalidated injection
The copper peptide has real, defined dosing as a topical cosmetic — and no validated dose, scant human data, and a copper-overload risk when injected. Route decides everything.
7 min readPeptidesPT-141 (bremelanotide) dosage: the one approved dose, and how community use departs from it
PT-141 is unusual — it has a real FDA-approved dose as Vyleesi: 1.75 mg subcutaneous, on demand, capped per day and per month. A precise read of that dose, and why off-label community dosing is unstudied.
7 min readPeptidesSemax dosage: the intranasal doses studied — and why none are FDA-approved
Semax is dosed intranasally and has real Russian clinical regimens, but no Western dosing standard. The stroke-trial doses, the modified acetyl-amidate form sold online, and community microdosing all carry different — and thin — levels of evidence.
7 min readLongevityMOTS-c dosage: there is no validated human dose
MOTS-c's evidence is almost entirely preclinical — the real dosing data is mg/kg in mice, which does not convert to a human protocol. The ranges traded online are unvalidated, experimental self-dosing.
7 min readPeptidesMelanotan II dosage: there is no safe dose, and here’s why
MT-2 has no approved or established safe dose — no regulator licenses it. The microgram protocols people share are folklore attached to an unverified powder, and the harms rise with the amount injected.
7 min readPeptidesIGF-1 LR3 dosage: there is no validated human dose — and why that matters
No regulator, label, or trial has ever set a dose for IGF-1 LR3. The microgram figures traded in bodybuilding circles are unvalidated folklore — and with an insulin-like, cancer-linked growth hormone, a wrong dose is genuinely dangerous, not just ineffective.
7 min readPeptidesDihexa dosage: why there is no established human dose
Dihexa has never been through a human clinical trial, so no dose has ever been validated for people. The only real numbers come from rodent mg/kg studies — and the microdoses circulated online are untested self-experimentation, not protocol.
6 min readPeptidesDSIP dosage: why there is no validated protocol
DSIP has no FDA approval and no established dose. The only defined human doses come from small 1980s IV studies; the microgram figures online are gray-market convention. The honest, evidence-first read.
6 min readPeptidesKPV dosage: why there is no established human dose
KPV's evidence is preclinical — mouse colitis and cell models, with no human trials. That means no validated dose, no proven route, and no safety profile. A straight read of what the numbers are, what they aren't, and why the circulating ranges are unvalidated self-experimentation.
6 min readPeptidesThymosin alpha-1 dosage: the 1.6 mg twice-weekly trial regimen, in context
The dose carried through thymosin α1's approved and trial use is consistent: 1.6 mg subcutaneously, twice weekly. But that's a supervised clinical regimen from sick patients — not a US-approved prescription, and not a validated wellness dose for healthy adults.
7 min readPeptidesHexarelin dosage: the studied doses, and why there's no safe standing protocol
Human studies used small weight-based hexarelin doses — roughly 1–2 µg/kg IV and 1.5–3 µg/kg SC — as one-off GH probes. But its GH effect desensitizes with continued use, it raises cortisol and prolactin, and it's an unapproved, unregulated drug. There is no sanctioned dose.
7 min readPeptidesHGH Fragment 176-191 dosage: why there's no validated dose to give
The microgram amounts circulated for HGH Fragment 176-191 are community conventions, not validated figures — there are no human efficacy trials of the raw fragment, and the one rigorous test of the idea (AOD-9604) failed to beat placebo.
7 min readPeptides5-Amino-1MQ dosage: why there is no validated human dose
5-Amino-1MQ has no human trials, so no established human dose exists. The only real numbers are rodent mg/kg figures that don't convert to people — the route is oral, but the amount is a question mark.
6 min readPeptidesKisspeptin dosage: research infusions, not a home-injection protocol
Kisspeptin was dosed in humans only as a clinician-delivered, weight-based IV infusion or supervised bolus in research — there is no validated at-home dose, route, or schedule, and the marketed vial has none behind it.
6 min readLongevityHumanin dosage: why there is no validated human dose
Humanin and its potent HNG analog have been dosed only in cells and animals — there is no human dosing trial and no established human dose. In people, humanin is a biomarker you measure, not a drug you take.
6 min readPeptidesTB-500 side effects: why “none reported” means “none studied”
Injectable TB-500 has no human safety data — so its side-effect profile is largely unknown, and the most credible concern is a theoretical cancer-biology risk built into the molecule's own mechanism.
7 min readPeptidesGHK-Cu side effects: why route is the whole story
Topical copper-peptide creams are generally well tolerated — but injected GHK-Cu has no human safety data and a real concern the skincare evidence never raises: copper overload.
6 min readPeptidesPT-141 (bremelanotide) side effects: trial-grade data led by nausea, plus a blood-pressure flag
Because PT-141 is FDA-approved as Vyleesi, its side effects are documented in real trials: nausea dominates, with a transient blood-pressure rise and possible skin darkening as the flags that matter — and off-label dosing amplifies all three.
7 min readPeptidesSemax side effects: a quiet record, and a much larger unknown
Semax is reported as generally well tolerated in short Russian studies, with local nasal irritation the most likely everyday effect. But it is unapproved, its BDNF mechanism raises long-term questions no trial has answered, and unregulated supply adds its own risk.
6 min readLongevityMOTS-c side effects: the human safety data simply doesn't exist
Animal studies haven't flagged overt toxicity at the doses tested — but there are no human safety trials, so MOTS-c's real side-effect profile in people is unknown, not proven safe.
6 min readPeptidesMelanotan II side effects: the mole problem, priapism and serious rare events
MT-2 has the most-documented harm record of any peptide here — nausea and flushing at the mild end, darkening and new moles that mask melanoma surveillance in the middle, and priapism, renal infarction and PRES at the dangerous end. Regulators warn against it.
7 min readPeptidesIGF-1 LR3 side effects: hypoglycemia, overgrowth, and the cancer concern
IGF-1 LR3 is one of the riskier peptides, and its side effects come straight from the biology: insulin-like hypoglycemia, acromegaly-style overgrowth, and the proliferation concern of chronically elevating a systemic growth factor — all amplified by the long-acting design.
7 min readPeptidesHexarelin side effects: the cortisol, prolactin and desensitization problems
Hexarelin's distinguishing side effects aren't a longer list — they're being non-selective (it raises cortisol and prolactin, unlike ipamorelin) and self-limiting (the GH effect fades with repeated dosing), plus the usual GH-axis complaints and a cardiac-receptor note. A straight read.
7 min readPeptidesDihexa side effects: unknown in humans, not proven safe
There are no human trials of dihexa, so its side-effect profile in people is genuinely unknown — “no reported side effects” reflects absent study, not safety. The one concern worth taking seriously is mechanistic: it activates the HGF/c-Met growth pathway implicated in cancer.
6 min readPeptidesDSIP side effects: a thin old record, no modern safety dataset
Older studies reported few acute problems — mostly headaches — but that comes from small 1980s work on a molecule whose biology is still unresolved. Why DSIP's safety in modern use is genuinely unestablished.
6 min readPeptidesKPV side effects: why “no reported side effects” isn’t reassurance
KPV has no human safety data — its whole profile comes from cells and animal models. Those studies didn’t flag toxicity at the doses tested, and KPV shouldn’t tan skin like melanotan, but neither makes it proven safe. A straight read of what’s known and what isn’t.
6 min readPeptidesThymosin alpha-1 side effects: real trial data, read against the online vial
Because Tα1 (brand Zadaxin) is an approved drug abroad, it has genuine trial-grade safety data — it reads as well tolerated, with injection-site reactions the main effect. The honest cautions are mechanistic (autoimmune flare, immunosuppression), and none of it describes the unregulated US peptide vial.
6 min readGLP-1Cagrilintide: the amylin analog behind CagriSema, on its own terms
Cagrilintide is a long-acting amylin analog — not a GLP-1 — that produced dose-dependent weight loss as a standalone weekly injection in Phase 2. A straight read of the monotherapy evidence and where it sits.
8 min readGLP-1Cagrilintide dosage: what the trials used, and why there's no approved dose
Cagrilintide is investigational — no FDA-approved standalone, so no sanctioned dose. The Phase 2 trial studied 0.3–4.5 mg once weekly, titrated slowly for tolerability and given under supervision. A straight read of trial dosing vs. self-dosing.
7 min readGLP-1Cagrilintide side effects: a gastrointestinal, titration-shaped profile
Amylin slows gastric emptying, so cagrilintide's side effects are mostly in the gut — nausea, vomiting, constipation, diarrhea — dose-related and usually transient. What the trials actually report.
7 min readLongevityGonadorelin: real GnRH with a proven pump role — and an unproven TRT-adjunct pitch
Gonadorelin is authentic synthetic GnRH with a legitimate diagnostic and pulsatile-pump fertility role — but the modern once-daily bolus use as an hCG substitute on TRT ignores the rhythm the evidence depends on.
8 min readPeptidesPeptides vs SARMs: a structural class versus a single drug class
They get cross-shopped constantly, but they're not the same kind of thing. “Peptides” is a broad structural category with many targets; SARMs are one drug class acting on a single receptor — with liver and testosterone risks peptides don't share.
8 min readPeptidesIpamorelin vs HGH: the hormone, or a request for the hormone?
HGH is recombinant growth hormone injected from outside; ipamorelin only asks your own pituitary to release its own. That exogenous-vs-endogenous split explains the potency gap, the risk profile, and why neither is an anti-aging answer.
7 min readPeptidesMK-677 vs HGH: can an oral pill replace injectable growth hormone?
MK-677 prompts your own pituitary to release more GH; HGH is the injected hormone itself. One is a never-approved research chemical, the other an approved medicine — and neither has proven anti-aging benefit.
7 min readPeptidesHexarelin vs ipamorelin: stronger but dirtier vs cleaner but milder
Two GHRPs, one receptor. Hexarelin is the more potent GH releaser but raises cortisol and prolactin and desensitizes with use; ipamorelin is the selective, sustainable 'clean' choice. Here is why the milder peptide won.
7 min readPeptidesBPC-157 vs TB-500: the recovery peptide pair, graded on evidence
They're sold as a matched 'healing stack,' but BPC-157 and TB-500 are unrelated molecules with different mechanisms — and the same honest ceiling: overwhelmingly preclinical for recovery, with no human randomized trials.
7 min readPeptidesThe BPC-157 + TB-500 blend (“Wolverine stack”): popular, but proven?
The combined recovery protocol has a tidy mechanistic story and zero combination trials. A straight read of what the blend is, the theory, and the gaps.
7 min readLongevityTRT and Hematocrit: Why Testosterone Thickens the Blood, and What to Do About It
Erythrocytosis is the most common lab change on testosterone therapy — predictable, route-dependent, and manageable with monitoring.
8 min readLongevityAnastrozole for Men: Does Blocking Estrogen Actually Help?
An aromatase inhibitor reliably raises testosterone and lowers estradiol in men — but routine use, especially on TRT, is off-label and risks the bone health estradiol protects.
8 min readLongevityFoods That Increase Testosterone: What the Evidence Actually Supports
Diet raises testosterone mainly by fixing a deficiency or reversing obesity — most “testosterone food” claims are hype.
8 min readLongevityTestosterone Therapy for Women: What the Evidence Actually Supports
Low-dose transdermal testosterone helps postmenopausal HSDD — and almost nothing else the marketing promises.
8 min readLongevityTUDCA: real bile-acid biology, an approved parent drug, and a failed flagship trial
TUDCA is a genuine ER-stress-calming chemical chaperone whose parent compound (UDCA/ursodiol) is an approved liver drug — but the longevity and broad supplement claims rest on mechanism and small or animal studies, and its highest-profile human program (ALS / Relyvrio) failed phase 3 and was withdrawn in 2024.
8 min readLongevityGotu Kola (Centella asiatica): What the Evidence Actually Shows
Strong for venous insufficiency and topical wound healing; the cognition and longevity claims rest on thin, mixed data.
7 min readLongevityAlpha-GPC: What the Evidence Actually Shows
A cholinergic precursor with real dementia-trial data, weak ergogenic studies, and an unresolved 2021 stroke-risk signal.
7 min readLongevityParaxanthine: The Evidence on Caffeine's Primary Metabolite
The well-characterized methylxanthine behind the “cleaner caffeine” pitch — what the small, mostly industry-funded human trials actually show.
8 min readLongevityBoron: What the Evidence Actually Shows About the “Testosterone Mineral”
A trace mineral that nudges free testosterone and estradiol in tiny short studies — with no evidence it builds muscle or treats low T.
7 min readLongevityAstragalus & TA-65: a real telomerase activator, an unproven anti-aging claim
Astragalus is an immune-tonic herb whose saponin cycloastragenol genuinely activates telomerase in cells — but the longevity pitch rests on small, industry-linked human studies, while the better clinical data sit in kidney and heart disease.
8 min readLongevityPhosphatidylserine: Evidence for Memory, Cortisol, and Cognitive Health
A membrane phospholipid with real biology, older positive cognition data on a form you can no longer buy, and a weaker case for the soy-derived version sold today.
7 min readPeptidesBest Peptides for Muscle Growth: An Evidence-Ranked Reality Check
We rank the peptides marketed for bodybuilding by the human data that actually exists — and none is approved or proven to build muscle.
8 min readPeptidesHow to Inject Peptides Subcutaneously: A Careful, Evidence-Based Walkthrough
The subcutaneous self-injection technique itself — supplies, site rotation, aseptic steps, and sharps disposal — framed as harm-reduction, not medical advice.
7 min readPeptidesHow to Cycle Peptides: What the Pharmacology Actually Supports
Most peptide “cycles” are forum convention, not trial data—here is where the real receptor biology ends and the bro-science begins.
7 min readPeptidesHow to Store Peptides: Shelf Life, Temperature, and Stability
Why lyophilized powder, refrigerated solution, and the enemies of stability decide whether your peptide is still the molecule you paid for.
6 min readPeptidesAOD-9604: the “anti-obesity drug” peptide that failed its own trials
A synthetic growth-hormone tail fragment built to burn fat. Its mechanism is real and its safety was clean — but the pivotal human obesity trial showed no significant weight loss versus placebo, and the program was discontinued.
6 min readPeptidesAOD-9604 dosage: what's used, and why the number is borrowed
AOD-9604 has no approved label and no validated dose — the ~300 mcg/day figure circulated online is borrowed from a clinical program that was discontinued after it failed to beat placebo.
6 min readLongevityHumanin: the first mitochondrial-derived peptide — real biology, no human trials
Discovered in 2001 in a surviving neuron, humanin is a genuine cytoprotective mitochondrial-derived peptide whose levels fall with age — but no randomized human trial shows that taking it does anything for people.
6 min readPeptidesTesamorelin before and after: the honest results timeline
Tesamorelin’s one trial-proven result is less visceral abdominal fat, measured over ~3–6 months — not muscle, not a leaner mirror, and not the dramatic physique photos being sold.
7 min readPeptidesCJC-1295 + ipamorelin before and after: the honest results timeline
The stack reliably raises your own GH and IGF-1 — a real biomarker. But the dramatic physique “before and after” has no controlled human trial behind it. Here’s the realistic week-by-week timeline.
8 min readPeptidesTesamorelin cost in 2026: brand Egrifta SV vs compounded, and why the gap is so big
Brand Egrifta SV is a specialty biologic (thousands/mo, via insurance); compounded tesamorelin runs ~$300–$600/month off-label. Here’s the honest cost-by-route breakdown — and why the same molecule has two prices.
8 min readPeptidesSermorelin cost in 2026: per-month pricing, the intro-vs-renewal trap, and what your subscription buys
Compounded sermorelin is cash-pay and sold by subscription — roughly $120–$200/month once the intro rate steps up. Here’s a provider-by-provider price comparison, injection vs oral, and how to read a plan on a true per-month basis.
8 min readPeptidesHow much does BPC 157 cost? The price is really a regulatory story
BPC 157 isn’t FDA-approved and sits in the FDA’s Category 2 for compounding — which pushed it into the “research use only” gray market. Here’s what it actually costs by route, and why the cheapest vial hides an unpriced risk.
8 min readPeptidesCJC-1295 & ipamorelin cost in 2026: what the blend actually costs per month
CJC-1295 and ipamorelin are sold as one combined blend, so the price you’re comparing is a bundle. Here’s the honest per-month breakdown — telehealth vs. clinic vs. gray-market — anchored to the evidence.
8 min readLongevityNAD therapy cost in 2026: IV vs. injection vs. oral, and what your money buys
NAD+ is priced by delivery format — IV infusions run a few hundred dollars a session, injections ~$200–$340/month, oral precursors from ~$44/month. The catch: cost runs inverse to evidence. Here’s the honest breakdown.
8 min readLongevityRapamycin cost in 2026: a cheap generic drug behind an off-label access premium
Sirolimus is an off-patent generic — a month of tablets is often ~$50–$100 with a coupon. So what does rapamycin really cost for longevity? Mostly the off-label telehealth access, not the pills. The honest breakdown, anchored to the evidence.
8 min readPeptidesIpamorelin vs sermorelin: two receptors, one growth-hormone pulse
They both raise your own growth hormone — but sermorelin pulls the GHRH-receptor lever and ipamorelin the ghrelin-receptor one. That receptor split explains the selectivity, the stacking, and which fits which goal.
8 min readPeptidesTesamorelin vs ipamorelin: an approved drug versus a research peptide
Different receptors, very different evidence. Tesamorelin is FDA-approved with randomized-trial data for HIV visceral fat; ipamorelin is a research-grade GH secretagogue with mechanism support only. An honest, evidence-weighted comparison.
8 min readPeptidesMK-677 cost in 2026: why the cheap oral research chemical isn’t actually cheap
MK-677 (ibutamoren) is an oral capsule or dropper, not an injectable — and it has almost no legitimate pharmacy route. The per-milligram sticker looks low (~$40–$90 a bottle), but it prices the powder, not the purity, the prescriber, or the legal status.
8 min readPeptidesGHK-Cu cost in 2026: one copper peptide, two completely different price worlds
GHK-Cu is sold both as a $20–$60 topical skincare serum and as a far pricier injectable “research” vial — the same molecule, two markets, two risk profiles. Here’s what each price actually buys, anchored to the evidence.
8 min readPeptidesPT-141 cost in 2026: approved Vyleesi vs the compounded market — what each actually costs
PT-141 has two prices: the FDA-approved Vyleesi autoinjector (specialty tier, HSDD only) and the off-label compounded nasal spray or injection nearly everyone is actually buying. Here’s why they cost worlds apart — and what each one buys.
8 min readLongevityGlutathione cost in 2026: IV drip vs. injection vs. oral, and what your money buys
Glutathione is priced by delivery route — IV “gluta drips” run $150–$300+ a session, IM injections ~$100–$250/month, oral capsules under ~$30/month. The catch: cost runs inverse to evidence. Here’s the honest breakdown.
8 min readLongevityNMN cost in 2026: price per gram, best value, and the regulatory cloud to know about
Oral NMN runs ~$30–$70/month at common doses — but the metric that compares brands is cost per gram, and there’s a U.S. regulatory question hanging over NMN’s supplement status. Here’s the honest, evidence-anchored breakdown.
8 min readPeptidesCJC-1295 & ipamorelin dosage: the circulated numbers vs. what's actually proven
There's no FDA-approved dose for either peptide. We explain the pharmacology behind the microgram figures people circulate — the saturation-dose idea, the timing, the stack logic — and why none of it is clinically validated.
9 min readPeptidesPeptides for muscle growth: an evidence ranking of what actually works
No peptide marketed for muscle growth has randomized human proof of bigger or stronger muscle. GH secretagogues move a biomarker; BPC-157 and TB-500 are animal-only; IGF-1 LR3 and follistatin are untested and WADA-banned. The molecule with real data is testosterone — not a peptide.
8 min readPeptidesHow to reconstitute peptides: the process, the math, and the honest caveat
Reconstitution is just dissolving a freeze-dried peptide back into bacteriostatic water — and the concentration is one division (mg ÷ mL). Here is how the process and the math actually work, why this is a clinician's job, and why precise arithmetic on an unverified gray-market powder still tells you nothing.
9 min readPeptidesIpamorelin dosage: the microgram numbers people circulate vs. what's actually proven
Ipamorelin has no FDA-approved dose. We explain the pharmacology behind the figures — the saturation-dose idea, the empty-stomach and before-bed timing, the CJC-1295 stack — and why none of it is clinically validated.
8 min readPeptidesDihexa: a striking preclinical nootropic with zero human evidence
An orally-active angiotensin-IV–derived compound famous for building synapses “more potently than BDNF” in the lab. The animal data are real — but there are no human trials, and its c-Met growth-pathway mechanism raises unanswered safety questions.
7 min readPeptidesDSIP (delta sleep-inducing peptide): a famous name, an unresolved science
A naturally-occurring nonapeptide named for the delta brain-waves it produced in 1977 rabbits — yet half a century on, its gene, receptor and real human benefit remain unconfirmed. The honest, evidence-first read.
8 min readPeptidesKPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)
KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.
7 min readPeptidesThymosin alpha-1 (Tα1): a real immune drug abroad, read against the wellness pitch
Tα1 (brand Zadaxin) is an approved immunomodulator in dozens of countries — for hepatitis, sepsis and severe infection, supervised. It is not FDA-approved, not the same as TB-500, and not the general anti-aging injectable sold online. The honest evidence, dosing and side-effect read.
8 min readPeptidesHexarelin: a potent GH peptide — with cortisol, prolactin and desensitization in the fine print
Hexarelin is one of the most potent GH secretagogues studied — that part is real. But unlike the selective ipamorelin it also raises cortisol and prolactin, its GH effect fades with repeated use, and it’s unapproved, gray-market, WADA-banned material. A straight read.
8 min readPeptidesMelanotan II (MT-2): a real skin-darkening drug with real, unapproved risks
MT-2 genuinely tans skin via the melanocortin-1 receptor — but it’s an unapproved gray-market injectable with a documented harm record, from priapism to changing moles. And it’s not the approved drug afamelanotide.
8 min readPeptidesMelanotan 1 vs Melanotan 2: an approved drug versus a gray-market injectable
They aren’t two doses of one peptide. Melanotan I became afamelanotide (Scenesse), an FDA-approved implant for the rare disease EPP. Melanotan II is the unapproved cosmetic injectable — broader at the receptor level, with documented harms.
8 min readPeptidesIGF-1 LR3: a real anabolic hormone, engineered to last — and untested in people
IGF-1 is a genuine anabolic hormone and “Long R3” is engineered to dodge its binding proteins so it lasts far longer. But there are zero human muscle-building trials — and the risks (hypoglycemia, the growth-factor/cancer concern, a WADA ban) follow straight from the biology.
9 min readPeptidesAdipotide: the “fat-targeting” peptide that worked in monkeys — and damaged their kidneys
Adipotide (FTPP / a prohibitin-targeting peptide) destroyed white fat’s blood supply and caused rapid weight loss in obese rhesus monkeys — but the same study found dose-dependent kidney toxicity, and it never reached approved human use. The honest evidence, and the gray-market caveat.
9 min readPeptidesHGH Fragment 176-191: the GH “fat-loss fragment,” read against the trial that failed
It’s the C-terminal tail of growth hormone, sold as the part that burns fat. The honest anchor: its developed cousin AOD-9604 reached human obesity trials and failed to beat placebo — and the raw fragment sold today has no human trials at all.
8 min readPeptidesSelank dosage: the honest answer to “how much” for an unapproved peptide
There is no FDA-validated Selank dose. Here’s what the limited Russian literature and user practice actually report — an intranasal nasal spray, dosed in short courses — and why every number is a convention, not a prescription.
8 min readPeptidesSelank side effects: well tolerated in small studies — but is it actually safe?
In the small, short Russian trials Selank was described as well tolerated, with mild effects (nasal irritation, occasional fatigue) and no benzodiazepine-style dependence. But thin, short-term evidence isn't proven long-term safety — and the gray-market supply is the real risk.
8 min readLongevityEpitalon (epithalon) dosage: the circulated short-course schedule vs. the (missing) standard
There is no FDA-approved epitalon dose. Here’s the short-course pattern people actually circulate — the ~10–20 day cycle, the “50 mg” vial confusion — and why every number is reported, not recommended.
8 min readLongevityTestosterone levels by age: the real reference ranges, honestly explained
There’s no official per-decade chart — labs use one adult reference range (harmonized to roughly 264–916 ng/dL in healthy young men). Levels do fall ~1%/year with age, but partly because of weight, not age alone — and a number is never a diagnosis.
9 min readLongevityTRT before and after: a realistic timeline of what testosterone therapy actually changes
For men with diagnosed low testosterone, the real “before and after” is a timeline: libido and mood early, modest body-composition change over months, energy the wildcard. Here’s what the trials show — and what the transformation photos leave out.
9 min readLongevityShilajit benefits: a few small studies, and a real purity problem
Shilajit is a mineral-rich mountain resin marketed heavily for men. One small trial reported higher testosterone in healthy men and another better sperm quality — but the evidence is small and short, and unpurified shilajit can carry lead, arsenic and mercury.
8 min readLongevityNAD injections: how to get them near you or online, and what the evidence really says
Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.
8 min readGLP-1Contrave side effects: nausea, the serious warnings, and the honest safety picture
Nausea is Contrave's most common side effect — but the parts that matter most are the bupropion-driven neuropsychiatric/suicidality warning and the seizure contraindication. Read straight from the label and the COR trials, against modest ~5–9% efficacy.
8 min readLongevityEpitalon side effects: what's actually known about epithalon safety
The small Russian studies call epitalon (epithalon) well tolerated — but the safety database is tiny, old and single-group, there's no long-term human data, telomerase activation raises a theoretical cancer question, and the real risk is unregulated gray-market supply. “Few reported effects” isn't “proven safe.”
8 min readGLP-1How to get Wegovy in 2026: the four legitimate routes
Wegovy is the semaglutide approved for weight management, so you don't need diabetes — you need a BMI of 30+ (or 27+ with a comorbidity) and a route. Here are the four: your doctor plus insurance, NovoCare self-pay, telehealth, and the compounding question.
9 min readPeptidesPeptide therapy cost in 2026: the four routes, and what your money actually buys
Most “peptide therapy” is compounded sermorelin at ~$120–$300/month via telehealth. Approved peptide drugs, clinic programs and gray-market powders each price differently — here’s the honest breakdown, anchored to the evidence.
9 min readPeptidesWhere to get peptides safely: the three routes, ranked by oversight
There are three real ways to obtain a peptide in 2026 — and they differ by one thing that matters: oversight. Here is how FDA-approved drugs, licensed compounding (503A/503B), and the 'research use only' gray market actually compare.
9 min readLongevityGlyNAC: impressive trials, an unsettled replication question
Glycine + NAC restores glutathione and improved a broad sweep of aging markers in randomized human trials — but those trials are small, single-group, and the one independent attempt missed its primary endpoint.
7 min readLongevitySulforaphane: real human data, in niches that aren't longevity
The broccoli-sprout Nrf2 activator has genuine randomized trials — for autism and type-2 diabetes. But its anti-aging claims are preclinical, and bioavailability depends heavily on the preparation.
7 min readGLP-1GLP-1 and hair loss: is it the drug, or the weight loss?
Hair shedding on Ozempic, Wegovy and Zepbound is usually telogen effluvium — a temporary, diffuse thinning triggered by rapid weight loss, not follicle damage. It's delayed, self-limited, and typically regrows.
6 min readGLP-1Alcohol and Ozempic: does a GLP-1 really make you drink less?
The 'I stopped wanting to drink' reports now have a randomized trial behind them — but it showed semaglutide cut how heavily people drank and their craving, more than whether they drank at all. It's promising and off-label.
6 min readGLP-1'Ozempic face': what it is, and what it isn't
The gaunt, hollowed look on GLP-1 drugs is facial fat-pad loss from rapid weight reduction — not a drug-specific skin effect. The evidence is reviews and case series, and it's managed like any volume loss.
6 min readGLP-1How to get Ozempic in 2026: the honest pathway
Ozempic is a diabetes drug — so how you get it depends on why you want it. For diabetes it's on-label and often covered; for weight loss it's off-label and usually points to Wegovy. Here's the real route, and the real cost.
7 min readGLP-1How to get Mounjaro in 2026: the honest pathway
Mounjaro is a diabetes drug; the same molecule for weight loss is Zepbound. For diabetes it's on-label and often covered; for weight loss, Zepbound is the route. Here's the real pathway and the ~$1,080 list price.
7 min readLongevityGlutathione: the master antioxidant, and where the evidence actually is
Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.
7 min readLongevityCalcium AKG (Rejuvant): a real metabolite, an overstated headline
Alpha-ketoglutarate declines with age and compresses morbidity in mice — genuinely interesting. But the viral 'about 8 years younger' claim comes from an uncontrolled, industry-linked clock study, and no human trial shows a hard outcome.
7 min readLongevityMethylene blue: the longevity 'biohack' that's actually a drug
Low-dose methylene blue has a plausible mitochondrial mechanism and a real single-dose memory signal — but it's an FDA-approved drug, not a supplement, its anti-aging claims are preclinical, and it can cause fatal serotonin syndrome with antidepressants.
7 min readGLP-1What the semaglutide weight-loss trials actually showed
STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.
6 min readPeptidesBPC 157: what the evidence actually shows (and what it doesn't)
The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.
6 min readPeptidesTB-500 and thymosin beta-4: separating the trials from the hype
Real Phase 2 dry-eye data, deep preclinical neuro/cardiac work, and a recovery-market use that was never actually tested.
6 min readPeptidesGHK-Cu: the copper peptide between real skincare and overclaim
A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.
6 min readPeptidesSermorelin: a real GHRH drug, read against the anti-aging pitch
An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.
6 min readGLP-1Oral semaglutide (Rybelsus): what the PIONEER trials actually showed
A GLP-1 peptide in a pill is hard to pull off. PIONEER 1, 4, and 6 plus OASIS 1 — read straight from the primary literature.
6 min readGLP-1Tirzepatide vs semaglutide for weight loss: what the trials actually support
Most comparisons are cross-trial. Only SURPASS-2 and SURMOUNT-5 randomized one drug against the other — here's the precise distinction.
7 min readGLP-1GLP-1 gastrointestinal side effects: incidence and timeline from the trials
Nausea, vomiting, diarrhea, constipation — how common they are and when they happen, read straight from the pivotal adverse-event tables.
7 min readLongevityNAD+ precursors (NR and NMN): what the human trials actually show
They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.
7 min readLongevityMetformin for longevity: TAME, MILES, and the healthspan hypothesis
A provocative survival signal, a credible mechanism, surrogate-level human data — but the definitive outcome trial hasn't reported. An honest grade.
7 min readGLP-1Compounded vs branded GLP-1: regulatory status, sourcing, and what the evidence actually says
Compounded GLP-1 isn't FDA-approved, its legality hinged on the shortage list, and the trial data belong to the branded product — here's the precise picture.
7 min readGLP-1GLP-1 medications and muscle: what the body-composition data actually show
Some of the weight lost is lean mass — but the substudies show fat falls faster, the ratio improves, and resistance training plus protein is what protects muscle.
7 min readGLP-1GLP-1 cost and insurance coverage: what drives the price, and what's actually covered
List price, net price, and your price are three different numbers. Indication drives coverage, savings cards have fine print, and cost is itself a clinical variable.
7 min readLongevityRapamycin for longevity: the PEARL trial and the human evidence
Gold-standard mouse lifespan data, randomized human trials on an immune surrogate, and a one-year PEARL safety read — but no evidence yet that it extends human healthspan.
7 min readLongevityTaurine and aging: what the Singh 2023 Science work and the human data actually show
A robust mouse lifespan result — but 2025 human data found taurine doesn't reliably decline with age, and the only human trials are small cardiometabolic ones.
7 min readGLP-1Retatrutide: the triple agonist and what its Phase 2 data actually show
A single peptide hitting GIP, GLP-1 and glucagon produced the largest weight-loss numbers yet reported — in Phase 2. A straight read of the evidence and its limits.
6 min readGLP-1Orforglipron: the oral non-peptide GLP-1, and what the trials actually show
A once-daily small-molecule GLP-1 pill with no food restrictions — from Phase 2 proof of concept to the Phase 3 read-outs. The evidence, graded.
6 min readGLP-1CagriSema: what the REDEFINE program actually showed
Amylin (cagrilintide) plus GLP-1 (semaglutide) in one weekly shot. REDEFINE 1 and 2 delivered large weight loss — and a more nuanced story than the hype. A straight read.
6 min readPeptidesTesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence
A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.
6 min readPeptidesIpamorelin & CJC-1295: the honest evidence on GH secretagogue peptides
They reliably raise growth hormone — that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.
6 min readPeptidesPeptides for weight loss: which ones actually work?
Only one class of peptides has real weight-loss trials behind it — the GLP-1 and incretin drugs. BPC-157, AOD-9604, the GH secretagogues and the rest are sold on mechanism, not outcomes. An evidence-first sort.
7 min readGLP-1Ozempic vs Wegovy: same drug, two labels, two dose ceilings
Ozempic and Wegovy are both semaglutide from the same maker — but approved for different uses at different max doses. An honest, evidence-first explainer.
6 min readPeptidesBPC-157 dosage and safety: why there is no validated human dose
The honest answer to a heavily-searched query: no established human dose, no dose-ranging trial, no approval, and no long-term safety data. Here is why.
6 min readPeptidesBPC-157 side effects and safety: what the thin human evidence actually shows
BPC-157 isn't FDA-approved and the human safety data are thin. The biggest real-world risk is unregulated, unverified-purity vials — and the missing long-term data is the headline.
6 min readPeptidesSermorelin side effects: the approved-drug safety record vs. the compounded reality
Sermorelin was once an FDA-approved drug (Geref) with a well-documented, mostly mild side-effect profile. What changed isn't the molecule — it's the supply chain.
7 min readGLP-1Semaglutide results timeline: how long Wegovy really takes to work
Weight loss on semaglutide is gradual and tied to a slow dose ramp. The pivotal trial reported ~14.9% — at 68 weeks. Here is the honest, trial-grounded trajectory.
7 min readPeptidesSermorelin dosage: the clinical history vs. the modern anti-aging claim
Sermorelin once had real, label-defined dosing — a diagnostic test and pediatric GH therapy. The popular adult anti-aging dose has no outcome trials behind it.
6 min readLongevityMOTS-c: real mitochondrial biology, absent human evidence
A genuine mitochondrial-derived peptide with interesting rodent data on metabolism and exercise — but no human outcome trials. Promising biology, not a proven therapeutic.
6 min readLongevityEpitalon (epithalon): the honest evidence behind the telomerase and longevity claims
Marketed for telomerase activation and life extension. The supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.
7 min readPeptidesTesamorelin dosage: the FDA-approved 2 mg dose vs. the off-label frontier
Tesamorelin (Egrifta) has one approved dose — 2 mg subcutaneous once daily for HIV-associated lipodystrophy. Its off-label anti-aging and fat-loss uses have no established dose.
6 min readPeptidesTesamorelin (Egrifta) side effects: the documented, label-monitored profile
Tesamorelin is FDA-approved, so it has a real side-effect record: injection-site reactions, joint and muscle pain, edema, plus mechanism-based IGF-1 and glucose monitoring.
7 min readPeptidesTesamorelin vs sermorelin: two GHRH analogs, very different status
Both stimulate your own growth hormone. Only tesamorelin is FDA-approved (HIV visceral fat); sermorelin is the shorter, now-compounded option. Neither is proven anti-aging.
7 min readPeptidesTesamorelin for bodybuilding: what the evidence does — and doesn't — show
It reliably cuts HIV-associated visceral fat and raises IGF-1 — that's real, and FDA-approved. But there are zero trials of tesamorelin for muscle or physique in healthy people.
7 min readPeptidesSermorelin before and after: what the evidence actually shows
Sermorelin’s real, trial-documented “before and after” is faster growth in GH-deficient children. The dramatic adult transformation photos have no controlled outcome trials behind them.
6 min readPeptidesBPC-157 before and after: what the evidence really shows about results
Searchers want proof of recovery transformations. The truth: BPC-157's results are almost entirely animal data plus anecdote — no controlled human before-and-after trials exist yet.
7 min readPeptidesPT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.
6 min readPeptidesKisspeptin: real reproductive-axis science, unproven as a sold therapy
A genuine human hormone atop the testosterone axis, with serious early human research — but the marketed libido and T-booster products are off-label extrapolations at unestablished doses.
7 min readLongevityEnclomiphene: the evidence for restoring testosterone without replacing it
Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.
8 min readGLP-1Zepbound vs Wegovy: what the trials actually show
Zepbound (tirzepatide) leads on weight loss in the one head-to-head trial; Wegovy (semaglutide) has the cardiovascular-outcomes approval. An honest comparison.
8 min readGLP-1Retatrutide vs tirzepatide: what the evidence actually shows
Retatrutide's ~24.2% Phase 2 weight loss edges tirzepatide's ~20.9% — but they're separate trials, there's no head-to-head, and one drug isn't even approved.
7 min readLongevityEnclomiphene vs TRT: same testosterone, opposite effect on fertility
Both raise testosterone — enclomiphene by stimulating the body's own production, TRT by replacing it. In trials they reached comparable levels; only TRT suppresses fertility.
8 min readLongevityEnclomiphene dosage: what the trials actually used
Studied as a once-daily oral dose of 6.25 to 25 mg, with 25 mg reaching testosterone comparable to a gel — but there's no FDA-approved schedule, and the product is compounded.
7 min readLongevityEnclomiphene side effects: what the trials actually found
Generally well tolerated, with fewer adverse events than clomiphene and no effect on thyroid, cortisol, lipids or bone — but the trials were small and short, and the product is compounded.
7 min readLongevityEnclomiphene vs clomid: is the purified isomer worth it?
Enclomiphene is clomiphene's isolated active half. It doesn't raise testosterone more — clomiphene did, on average — but it's cleaner on estradiol and side effects.
7 min readLongevityHow to get enclomiphene: the legitimate route, and the trap to avoid
No FDA-approved product means it reaches men through an off-label prescription and a compounding pharmacy. Here's the legitimate path — and why gray-market 'research' sellers aren't a shortcut.
6 min readGLP-1Zepbound cost in 2026: list price, self-pay, and the $25 copay
The ~$1,086 list price is one almost no one pays. Self-pay vials run $299–$449 by dose; with covered insurance the savings card drops the copay to as little as $25.
7 min readGLP-1Wegovy cost in 2026: list price, self-pay, and the $25 copay
The ~$1,349 list price is one most people don't pay. Self-pay is $199/month for two months then $349 on the pen, from $149 for the pill, and as low as $25 with covered insurance.
7 min readGLP-1How to get Zepbound: the three routes to a prescription
Zepbound is prescription-only. Here's who qualifies, and the three legitimate routes — your clinician, telehealth, or LillyDirect — plus why there's no legal no-prescription shortcut.
6 min readPeptidesTesofensine: the striking weight-loss number with a big asterisk
A triple monoamine reuptake inhibitor repurposed from a failed Alzheimer's drug. Its ~9.2% Phase II weight loss is real but flagged — a Lancet Expression of Concern, no Phase III, no approval.
7 min readPeptides5-Amino-1MQ: an elegant mechanism with no human trials
An NNMT inhibitor that reverses obesity in mice by sparing the NAD+ pool — without reducing food intake. The mechanism is plausible; the human evidence is nonexistent.
6 min readPeptidesSemax: a real Russian nootropic with an under-tested evidence base
An ACTH(4-10)-derived heptapeptide that raises BDNF and is a registered drug in Russia. The mechanism is credible — but the human evidence is small, single-country, and mostly uncontrolled.
7 min readPeptidesSelank: a non-benzodiazepine anxiolytic peptide, lightly tested
A tuftsin-analog heptapeptide that modulates GABA without being a benzodiazepine — and matched benzodiazepines in small Russian trials. The mechanism is credible; the evidence base is thin.
7 min readPeptidesMK-677 (ibutamoren): raises the hormones, not (yet) the outcomes
An oral ghrelin mimetic that reliably lifts GH, IGF-1 and lean mass in human trials — but the same trials found no gain in strength, function or cognition, plus real metabolic and cardiac safety signals.
8 min readPeptidesMK-677 dosage: what the trials actually used
Nearly every human trial used 25 mg once daily, oral — the dose that lifts GH and IGF-1 into the young-adult range over about a month. But there's no FDA-approved dose, and the product is unregulated.
6 min readPeptidesMK-677 side effects: the blood-sugar problem and a cardiac flag
Beyond the appetite and water retention, MK-677 consistently raises fasting glucose and reduces insulin sensitivity — and a hip-fracture trial was stopped early for a heart-failure signal.
7 min readPeptidesMK-677 vs sermorelin: oral secretagogue or injectable GHRH analog?
Both raise GH and IGF-1, but by different pathways. Sermorelin is an approved (now compounded) GHRH analog; MK-677 is a never-approved oral pill with clearer metabolic and cardiac flags.
7 min readLongevityUrolithin A (Mitopure): real trials, modest results
A mitophagy-inducing postbiotic with unusually strong RCT evidence for a supplement — that reproducibly improves muscle endurance and biomarkers while repeatedly missing its primary strength endpoints.
7 min readLongevitySpermidine: a great longevity story, still waiting on the trials
A polyamine that induces autophagy, extends lifespan in mice, and tracks with lower mortality in population studies — but the association is observational, and the best human trial found no effect.
7 min readLongevityFisetin: a powerful senolytic in mice, unproven in humans
A dietary flavonoid that's the most potent senolytic of its class and extends lifespan in mice — but the human trials that would test the senolytic claim are still ongoing, with no published outcomes.
7 min readLongevityNAD+ IV therapy: an expensive drip ahead of its evidence
Clinics sell NAD+ infusions for anti-aging, energy and addiction at $250–$1,500 a session — but there's no controlled trial of IV NAD+, and the real human evidence is for oral precursors, not the drip.
7 min readGLP-1Mounjaro vs Ozempic: what the head-to-head trial actually found
In SURPASS-2, a direct randomized trial, Mounjaro (tirzepatide) beat Ozempic (semaglutide) on both blood sugar and weight — likely because it hits two gut-hormone receptors instead of one.
6 min readGLP-1Trulicity vs Ozempic: the head-to-head trial result
Both are once-weekly GLP-1 injections for diabetes. In SUSTAIN-7, semaglutide (Ozempic) beat dulaglutide (Trulicity) on both blood sugar and weight at matched doses — about 6.5 kg vs 3.0 kg.
6 min readGLP-1Wegovy vs Saxenda: the head-to-head wasn't close
Both are weight-loss GLP-1 injections, but in STEP 8 the newer once-weekly Wegovy produced ~15.8% weight loss versus ~6.4% for the daily Saxenda — and was more convenient too.
6 min readGLP-1Rybelsus vs Ozempic: same drug, pill versus injection
Rybelsus and Ozempic are both semaglutide — one a daily pill, one a weekly injection. The injection reaches higher potency; the pill is needle-free but comes with strict empty-stomach dosing rules.
6 min readLongevityBerberine: real evidence for blood sugar, not for weight loss
A plant alkaloid that activates AMPK and lowers glucose and LDL in human trials — with effects on blood sugar comparable to oral diabetes drugs. But it's not a GLP-1, and 'nature's Ozempic' is a myth.
8 min readLongevityBerberine vs metformin: same switch, very different evidence
Both activate AMPK, and in a small head-to-head berberine's glucose-lowering matched metformin's. But metformin is an approved drug with decades of data; berberine is a low-certainty supplement.
6 min readLongevityBerberine vs Ozempic: why 'nature's Ozempic' is a myth
Berberine and Ozempic work by completely different mechanisms — AMPK vs GLP-1 — and produce completely different results: no significant weight change for berberine versus ~15% for semaglutide.
6 min readLongevityBerberine dosage: how much, when, and the safety catches
Trials used 500 mg two to three times daily with meals — split because berberine is barely absorbed (under 1%). Plus the GI effects, drug interactions, and the firm pregnancy contraindication.
6 min readLongevityTRT: what testosterone therapy is actually proven to do
An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.
8 min readLongevityTRT side effects: the real risks, and the monitoring that manages them
Testosterone therapy reliably thickens the blood (most with injections), suppresses fertility, and — per TRAVERSE — raised atrial fibrillation, clots and kidney injury. Here's what monitoring catches.
7 min readLongevityHow to get TRT online: the diagnosis pathway, and the red flags
TRT is prescription-only and needs a real diagnosis — symptoms plus low testosterone on two morning labs. Here's the legitimate telehealth flow, and why 'prescribed from a questionnaire' is the warning sign.
6 min readLongevityTRT cost: insurance copay vs cash telehealth, and what drives the price
TRT for diagnosed hypogonadism is often insurance-covered and the drug is cheap; cash all-inclusive telehealth runs $99–$225/month. Injections are cheapest — and you may be overpaying for a covered drug.
6 min readLongevityQuercetin: one real benefit, and a reputation that outruns it
A flavonoid with modest, meta-analysis-backed blood-pressure benefit — but its 'senolytic' fame belongs to the dasatinib+quercetin combo, and its exercise and allergy claims are weak.
7 min readLongevityResveratrol: spectacular in mice, disappointing in humans
The 'red wine longevity molecule' extended lifespan in yeast and mice via SIRT1 — but human trials show only modest benefit in diabetics, nothing in healthy people, and it even blunted exercise gains.
7 min readGLP-1Metformin vs Ozempic: different drugs, often used together
Not really rivals — metformin is the cheap, oral, first-line foundation; Ozempic (semaglutide) is a more potent injectable that adds greater glucose-lowering and real weight loss.
6 min readGLP-1Mounjaro vs Zepbound: the same drug under two names
Both are tirzepatide — identical molecule, identical 15 mg dose ceiling, identical ~20.9% weight loss. Mounjaro is the diabetes brand, Zepbound the obesity brand; diagnosis and insurance decide which you get.
6 min readGLP-1Contrave vs Wegovy: the weight-loss gap is large
Both are approved weight-loss drugs, but Wegovy (a GLP-1 injection) produced ~14.9% weight loss versus ~6.1% for the oral Contrave — about 2.5 times more. Contrave's niche is being needle-free.
6 min readLongevityTRT vs natural testosterone: what actually works?
Losing excess weight and fixing short sleep genuinely raise testosterone; exercise helps mostly via fat loss; zinc and vitamin D only if you're deficient; and most 'boosters' don't work. When that isn't enough, TRT is.
7 min readLongevityLow testosterone treatment: the stepwise options that actually work
Confirm it's real, fix any reversible cause (weight, sleep, medications) first, then choose the medication — TRT for confirmed hypogonadism, enclomiphene or hCG when fertility matters.
7 min read